EP Patent

EP3360538B1 — Injectable flowable composition comprising buprenorphine

Assigned to Indivior UK Ltd · Expires 2023-02-15 · 3y expired

What this patent protects

Patent listed against Risperdal.

Drugs covered by this patent

Risperdal (risperidone) · Johnson & Johnson (Janssen)

Patent Metadata

Patent number: EP3360538B1
Jurisdiction: EP
Classification: —
Expires: 2023-02-15
Drug substance claim: No
Drug product claim: No
Assignee: Indivior UK Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.